Insider filing · ALMS

Srinivas Akkaraju bought $1.4M of Alumis (ALMS)

Executed Nov 13 2025, disclosed Nov 17 2025, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 17 2025), the stock returned +106.5% (delay-adjusted); from the execution session (Nov 13 2025), +122.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

SA Srinivas Akkaraju Director profile →

Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23.

ALMS Alumis Inc. ALMS · Healthcare · 24 filings in 24 months ticker →

Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→